Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore

Key Points

• Cost-effectiveness of the bivalent vaccine may improve infant health outcomes against RSV illness,
• The analysis indicates a potential cost reduction of 25% in hospitalizations due to RSV in infants with maternal vaccination,
• Evaluated through a cost-effectiveness analysis comparing the bivalent maternal vaccine with routine care for RSV prevention,
• Results support the wider implementation of the maternal vaccine, highlighting its potential to reduce healthcare burdens on families.